Viewing 2 reply threads
  • Author
    • #20056

      “Researchers identify a cellular defect common to familial and sporadic forms of ALS”

      A recent NIH-funded study may point to a possible therapeutic target for the disease.

      Read the announcement here:


      What do you think of this breakthrough? Does it hold promise for ALS patients? Especially when it identifies a cell defect that is shown to be common in both sporadic and familial ALS.

    • #20077

      This is where it gets interesting;


      ” If an antisense oligonucleotide drug, which stops cells from manufacturing specific proteins, was used to decrease the amount of CHMP7 within the ALS neurons, the pore never degraded. “

    • #20097

      If past history of so-called ALS treatment breakthroughs are any indication of any possible future ALS treatments, then this too will fizzy out into obscurity.




      • #20109

        Dr. Rothstein works in ALS research since a long time (~20 years?). But what is presented here is not very impressive. Working with iPSC-derived is something that could be done at little cost now, and (fortunately) many teams are working on ways to mitigate TDP-43 aggregates.
        And it only pushes the goal post further away: What makes CHMP7 aggregate in the nucleus?

        I guess this work has two objectives:
        1. Participating in the run to patent TDP-43 therapies.
        2. Showing to funding parties that the lab is doing something with their money.

Viewing 2 reply threads
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account

Verify you are not a robot